Products for Research Use Only

Pivanex

CAT: 0804-HY-120508-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120508-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties[1].
CAS Number
122110-53-6
Product Name Alternative
AN-9; Pivalyloxymethyl butyrate
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Bcr-Abl; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pivanex.html
Purity
95.0
Solubility
DMSO : ≥ 100 mg/mL
Smiles
CCCC(OCOC(C(C)(C)C)=O)=O
Molecular Formula
C10H18O4
Molecular Weight
202.25
Precautions
H302, H315, H319, H335
References & Citations
[1]Rabizadeh E, et al. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leuk Res. 2007 Aug;31 (8) :1115-23. Epub 2007 Jan 30.|[2]Batova A, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002 Nov 1;100 (9) :3319-24.|[3]Edwards JD, et al. Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy. J Neuromuscul Dis. 2016 Nov 29;3 (4) :511-515.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HDAC

Popular Products